A Single-Center,Open-Label,Randomized,3-Treatment,3-Period Cross-Over Study to Investigate the Potential Effect of Cyclosporine on the Pharmacokinetics, Safety, and Tolerability of Ticagrelor and the Effect of Ticagrelor on the Pharmacokinetics, Safety, and Tolerability of Cyclosporine.

Trial Profile

A Single-Center,Open-Label,Randomized,3-Treatment,3-Period Cross-Over Study to Investigate the Potential Effect of Cyclosporine on the Pharmacokinetics, Safety, and Tolerability of Ticagrelor and the Effect of Ticagrelor on the Pharmacokinetics, Safety, and Tolerability of Cyclosporine.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2014

At a glance

  • Drugs Ciclosporin (Primary) ; Ticagrelor (Primary)
  • Indications Acute coronary syndromes; Embolism and thrombosis; Heart transplant rejection; Liver transplant rejection; Pancreas transplant rejection; Plaque psoriasis; Renal transplant rejection; Rheumatoid arthritis; Transplant rejection
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 27 May 2014 Results published in the Clinical Drug Investigation.
    • 01 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 24 Jan 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top